HKG:0950

3 stories mentioning HKG:0950Updated just now

Every FINWIRES story that references HKG:0950, newest first.

Lee's Pharma Licenses Cancer Drug OC-3 From 1cBio; Shares Plummet 4%

Lee's Pharmaceutical (HKG:0950) said its wholly owned subsidiary Lee's Pharmaceutical (HK) signed an exclusive licensing agreement with US biotech company 1cBio for OC-3, a PARP1 inhibitor for cancer treatment.The license covers development, manufacturing and commercialization of OC-3 in mainland China, Hong Kong, Macau, Taiwan and certain Southeast Asian countries, according to a Wednesday Hong Kong bourse filing.Lee's Pharma shares fell over 4% in recent trade.

HKG:0950

Asia85d ago

Lee's Pharmaceutical Launches HK$50 Million Share Buyback; Shares Jump 8%

Lee's Pharmaceutical (HKG:0950) said it was launching an up to HK$50 million share buy back, according to a Tuesday filing with the Hong Kong bourse.The company said its current share price does not reflect its intrinsic value, representing a good opportunity to conduct the buyback.Shares of the company jumped nearly 8% in late morning trade Wednesday.

HKG:0950

Asia100d ago

Lee's Pharmaceutical to Receive Gates Foundation Funding

The Gates Foundation selected Lee's Pharmaceutical (HKG:0950) to receive funding for its synthetic surfactant project, according to a Monday filing with the Hong Kong bourse.The pharmaceutical company's shares gained nearly 2% in morning trade Tuesday.The funding will support the development of the active pharmaceutical ingredient and manufacturing processes for the drug.Long term, the project is meant to bring the life-saving medication to low- and middle-income countries to help premature infants suffering from respiratory distress syndrome.

HKG:0950

Track with the FINWIRES app suite

FolioX

Track HKG:0950 in your portfolio

WheelAI

Analyze HKG:0950 options with the wheel strategy

StockInsider

See market sentiment on HKG:0950